ArticleBMC geriatrics2023
Plasma acylcarnitine in elderly Taiwanese: as biomarkers of possible sarcopenia and sarcopenia.
Article in BMC geriatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.
- Systematic review and meta-analysis of biomarkers of sarcopenia and sarcopenic obesity.Medicine · 2026Pooled it
- Pathophysiological Mechanisms Underlying Sarcopenia and Sarcopenic Obesity: A Systematic Review and Meta-Analysis of Biomarker Evidence.International journal of molecular sciences · 2025Pooled it
- Mild cognitive impairment and pre-frailty show distinct plasma multi-omic signatures: a cross-sectional study.GeroScience · 2026Article
- Exploratory plasma metabolomics of aging-related associations with muscle quality and pulmonary function.GeroScience · 2026Article
- Biomarkers of Sarcopenia: Current Status and Future Perspectives.Aging medicine (Milton (N.S.W)) · 2026Review
- Integrative analysis of plasma small-molecule and gut-microbiome markers of sarcopenia in a pilot study within an Indian cohort.Scientific reports · 2026Article
- The Diagnostic Accuracy of Biological Markers of Sarcopenia, Sarcopenic Obesity, and Osteosarcopenia: Protocol for a Systematic Review and Meta-Analysis.Health science reports · 2025Article
- Association between sarcopenia and components of metabolic syndrome among Chinese older adults: a population-based longitudinal study using CHARLS.BMC public health · 2025Article
- Aging-Related Sarcopenia: Metabolic Characteristics and Therapeutic Strategies.Aging and disease · 2024Review
- Article
- Metabolic signatures of combined exercise and fasting: an expanded perspective on previous telomere length findings.Frontiers in aging · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundSarcopenia is defined as the disease of muscle loss and dysfunction. The prevalence of sarcopenia is strongly age-dependent. It could bring about disability, hospitalization, and mortality. The purpose of this study was to identify plasma metabolites associated with possible sarcopenia and muscle function to improve disease monitoring and understand the mechanism of muscle strength and function decline.
methodsThe participants were a group of healthy older adult who live in retirement homes in Asia (Taiwan) and can manage their daily lives without assistance. The participants were enrolled and divided into four groups: control (Con, n = 57); low physical function (LPF, n = 104); sarcopenia (S, n = 63); and severe sarcopenia (SS, n = 65) according to Asian countries that used Asian Working Group for Sarcopenia (AWGS) criteria. The plasma metabolites were used and the results were calculated as the difference between the control and other groups.
resultsClinical parameters, age, gender, body mass index (BMI), hand grip strength (HGS), gait speed (GS), blood urea nitrogen (BUN), hemoglobin, and hematocrit were significantly different between the control and LPF groups. Metabolite patterns of LPF, S, and SS were explored in our study. Plasma kynurenine (KYN) and acylcarnitines (C0, C4, C6, and C18:1-OH) were identified with higher concentrations in older Taiwanese adults with possible sarcopenia and S compared to the Con group. After multivariable adjustment, the data indicate that age, BMI, and butyrylcarnitine (C4) are more important factors to identify individuals with low physical function and sarcopenia.
conclusionThis metabolomic study raises the importance of acylcarnitines on muscle mass and function. It suggests that age, BMI, BUN, KYN, and C4/Cr can be important evaluation markers for LPF (AUC: 0.766), S (AUC: 0.787), and SS (AUC: 0.919).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.